logo-loader
viewIQ-AI Limited

IQ-AI receives first commercial order for StoneChecker

South Korea is a key market for IQ-AI, with recent research estimating that there are about 300,000 new cases of kidney stone disease each year, despite having a relatively small population of 51mln

kidney x ray
StoneChecker received European CE clearance last December

IQ-AI Limited (LON:IQAI) has announced the first commercial sale of its StoneChecker kidney stone medical imaging software.

The company’s South Korean distributor received the order from a “prominent” hospital in the country.

READ: IQ-AI hails South Korean distribution deal

“We are delighted to announce this significant commercial milestone for StoneChecker Software,” said IQ-AI chief operating officer David Smith.

“The enthusiasm and commercial interest with which the product has been greeted upon its introduction to South Korea bodes well for the global market. We look forward to making further announcements as we expand distribution.”

South Korea is a key market for IQ-AI, with recent research estimating that there are about 300,000 new cases of kidney stone disease each year, despite having a relatively small population of 51mln.

StoneChecker received European CE clearance last December, while approval from US regulators is expected soon.

Quick facts: IQ-AI Limited

Price: 3.2 GBX

LSE:IQAI
Market: LSE
Market Cap: £4.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: More from Imaging Biometrics on the AI deal

IQ-AI Limited’s (LON:IQAI) subsidiary, Imaging Biometrics (IB) recently signed a global distribution deal for imaging analysis software designed to detect chronic liver disease (CLD) and CEO Mike Schmainda tells Proactive why that's been so significant. Under the agreement with US firm AI...

on 15/1/20

2 min read